We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Affymetrix, Inc. | NASDAQ:AFFX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 14.01 | 0 | 01:00:00 |
From May 2019 to May 2024
Affymetrix Inc. (AFFX) and TessArae LLC said the Food and Drug Administration has granted emergency use authorization for a H1N1 influenza detection panel.
Shares rose 9.6% premarket to $6.08. The stock has nearly doubled this year.
The product was created by privately held TessArae using technology from Affymetrix, which makes products to help analyze genetic information.
TessArae's product isn't the only one to receive such emergency clearance from the FDA for H1N1 detection, but the company said one of its product's unique aspects is that it "directly generates genomic sequence from multiple influenza virus genes" to identify the particular H1N1 virus strain in a single test.
-By Kevin Kingsbury; Dow Jones Newswires; 212-416-2354; kevin.kingsbury@dowjones.com
1 Year Affymetrix Chart |
1 Month Affymetrix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
